Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir

AVIATOR, a phase 2 clinical trial, evaluated ritonavir-boosted paritaprevir (a protease inhibitor), ombitasvir (an NS5A inhibitor), and dasabuvir (a nonnucleoside polymerase inhibitor) (the three-drug [3D] regimen) with or without ribavirin (RBV) for 8, 12, or 24 weeks in 406 HCV genotype 1 (GT1)-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Preethi, Tripathi, Rakesh, Schnell, Gretja, Reisch, Thomas, Beyer, Jill, Irvin, Michelle, Xie, Wangang, Larsen, Lois, Cohen, Daniel, Podsadecki, Thomas, Pilot-Matias, Tami, Collins, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2015
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538512/
https://www.ncbi.nlm.nih.gov/pubmed/26100711
http://dx.doi.org/10.1128/AAC.00998-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538512/
https://www.ncbi.nlm.nih.gov/pubmed/26100711
http://dx.doi.org/10.1128/AAC.00998-15

Ejemplares similares